Quantcast
Last updated on April 23, 2014 at 12:16 EDT

Latest Debiopharm Group Stories

2012-07-23 22:20:42

LAUSANNE, Switzerland, July 24, 2012 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced the treatment of its first patient in a multicentre, open, non-comparative Phase III study to investigate the efficacy, safety, and pharmacokinetics of two subcutaneous (SC) injections of Debio 8206...

2012-06-19 02:28:29

SEATTLE and LAUSANNE, Switzerland, June 19, 2012 /PRNewswire/ -- Today, Immunexpress Group, Debiopharm Group(TM) (Debiopharm) and Biocartis announced a worldwide exclusive, royalty-bearing license for the late-stage development and commercialization of SeptiCyte® Triage - a multiplex gene expression assay for use in Emergency and Intensive Care Units (ICUs) or upon hospital admission to diagnose sepsis early, differentiate sepsis from other forms of inflammation, and determine sepsis...

2012-06-17 22:22:15

LAUSANNE, Switzerland and SUZHOU, China, June 18, 2012 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a global biopharmaceutical development group that focuses on serious medical conditions and particularly oncology, and Ascepion Pharmaceuticals, Inc. (Ascepion), a privately-held, biopharmaceutical company dedicated to the discovery and development of breakthrough small molecule drugs for the treatment of oncology and related diseases, have entered into an exclusive...

2012-06-17 22:22:13

LAUSANNE, Switzerland, and SUZHOU, China, June 18, 2012 /PRNewswire-Asia/ -- Debiopharm Group(TM) (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Ascepion Pharmaceuticals, Inc. (Ascepion), a privately-held, biopharmaceutical company dedicated to the discovery and development of breakthrough small molecule drugs for the treatment of oncology and related diseases, have entered into an...

2012-06-05 22:20:50

LAUSANNE, Switzerland, June 6, 2012 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, presented results of a Phase I open-label dose-escalation study with Debio 0932, an oral Heat Shock Protein 90 (HSP90) inhibitor in clinical development as an anti-cancer agent. The study was designed to determine the...

2012-05-14 22:20:48

LAUSANNE and VILLARS-SUR-GLÂNE, Switzerland, May 15, 2012 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm) and Vifor Pharma announce the signing of an exclusive agreement covering the distribution and commercialization in Switzerland of the 1-, 3- and 6-month formulations of Pamorelin(R)LA and of the 3-month formulation of Salvacyl(R). The agreement came into effect on 9 May 2012. Pamorelin(R) LA, which contains the active substance triptorelin in the form of...

2012-02-16 06:00:00

LAUSANNE, Switzerland and LEXINGTON, Massachusetts, February 16, 2012 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, and Debiopharm Group (Debiopharm), a group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that Debiopharm has begun treating patients in a Phase Ib clinical trial of Heat Shock Protein 90 (HSP90)...

2011-11-09 04:07:00

LAUSANNE, Switzerland, November 9, 2011 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics, presents the 2011 'Debiopharm /Valais Award' to Augurix Diagnostics (Augurix), a privately held company based in Monthey (Valais), that focuses on point-of-care testing in the field of gastro-enterology and initially on Celiac disease. Debio R.P., the Martigny-based structure of...

2011-10-05 03:00:00

LAUSANNE, Switzerland, October 5, 2011 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics, today presented the 'JCA-Mauvernay Award' to Doctor Hirofumi Arakawa from the National Cancer Center Research Institute in Tokyo, for his basic research on the 'identification and characterization of p53 target genes' and to Doctor Mineo Kurokawa from the University of Tokyo, for his...

2011-09-08 03:00:00

LAUSANNE, Switzerland, September 8, 2011 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics, will present tomorrow the 'Debiopharm Group Life Sciences Award 2011' to Professor Stefano Piccolo as well as two inaugural 'Junior Debiopharm Group Life Sciences Awards 2011' to Professor Etienne Meylan and Doctor Volker Busskamp. The award ceremony will take place at the EPFL (Ecole...